Bristol-Myers Squibb Co. BMY
i
Market dataready · fetched 2026-11-14T21:30:37.342Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-14T00:00:00.002564579Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-14T21:30:37.006512+00:00
Bristol-Myers Squibb Co. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 66.19 | 37.5% | 4.9% | 60.37 | 47.8% | 5.5% |
| 25Δ | 65.69 | 37.9% | 4.3% | 61.14 | 44.9% | 4.5% |
| 30Δ | 65.16 | 37.1% | 3.6% | 61.76 | 42.4% | 3.7% |
| 35Δ | 64.74 | 37.8% | 3.2% | 62.21 | 44.6% | 3.3% |
| 40Δ | 64.36 | 39.3% | 2.9% | 62.59 | 49.5% | 3.2% |
| 45Δ | 63.98 | 40.5% | 2.6% | 63.07 | 51.1% | 2.9% |
| 50Δ | 63.58 | 38.7% | 2.2% | 63.52 | 46.2% | 2.3% |
| 55Δ | 63.18 | 36.9% | 1.7% | 63.98 | 41.3% | 1.7% |
| 60Δ | 62.79 | 36.3% | 1.4% | 64.44 | 41.6% | 1.4% |
| 65Δ | 62.39 | 37.0% | 1.2% | 64.91 | 42.2% | 1.2% |
| 70Δ | 61.90 | 38.8% | 1.0% | 66.17 | 57.7% | 1.3% |
| 75Δ | 61.28 | 41.8% | 0.9% | 66.95 | 58.4% | 1.0% |
| 80Δ | 60.64 | 43.3% | 0.7% | 67.97 | 60.7% | 0.8% |
20Δ
- Pseudo strike
- 66.19
- IV
- 37.5%
- B/E move
- 4.9%
- Pseudo strike
- 60.37
- IV
- 47.8%
- B/E move
- 5.5%
25Δ
- Pseudo strike
- 65.69
- IV
- 37.9%
- B/E move
- 4.3%
- Pseudo strike
- 61.14
- IV
- 44.9%
- B/E move
- 4.5%
30Δ
- Pseudo strike
- 65.16
- IV
- 37.1%
- B/E move
- 3.6%
- Pseudo strike
- 61.76
- IV
- 42.4%
- B/E move
- 3.7%
35Δ
- Pseudo strike
- 64.74
- IV
- 37.8%
- B/E move
- 3.2%
- Pseudo strike
- 62.21
- IV
- 44.6%
- B/E move
- 3.3%
40Δ
- Pseudo strike
- 64.36
- IV
- 39.3%
- B/E move
- 2.9%
- Pseudo strike
- 62.59
- IV
- 49.5%
- B/E move
- 3.2%
45Δ
- Pseudo strike
- 63.98
- IV
- 40.5%
- B/E move
- 2.6%
- Pseudo strike
- 63.07
- IV
- 51.1%
- B/E move
- 2.9%
50Δ
- Pseudo strike
- 63.58
- IV
- 38.7%
- B/E move
- 2.2%
- Pseudo strike
- 63.52
- IV
- 46.2%
- B/E move
- 2.3%
55Δ
- Pseudo strike
- 63.18
- IV
- 36.9%
- B/E move
- 1.7%
- Pseudo strike
- 63.98
- IV
- 41.3%
- B/E move
- 1.7%
60Δ
- Pseudo strike
- 62.79
- IV
- 36.3%
- B/E move
- 1.4%
- Pseudo strike
- 64.44
- IV
- 41.6%
- B/E move
- 1.4%
65Δ
- Pseudo strike
- 62.39
- IV
- 37.0%
- B/E move
- 1.2%
- Pseudo strike
- 64.91
- IV
- 42.2%
- B/E move
- 1.2%
70Δ
- Pseudo strike
- 61.90
- IV
- 38.8%
- B/E move
- 1.0%
- Pseudo strike
- 66.17
- IV
- 57.7%
- B/E move
- 1.3%
75Δ
- Pseudo strike
- 61.28
- IV
- 41.8%
- B/E move
- 0.9%
- Pseudo strike
- 66.95
- IV
- 58.4%
- B/E move
- 1.0%
80Δ
- Pseudo strike
- 60.64
- IV
- 43.3%
- B/E move
- 0.7%
- Pseudo strike
- 67.97
- IV
- 60.7%
- B/E move
- 0.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 26.36% | |
| 28.24% | |
| 28.99% | |
| 26.50% | |
| 27.69% | |
| 27.75% | |
| 27.30% | |
| 26.29% | |
| 23.28% | |
| 24.88% | |
| 24.48% | |
| 24.77% | |
| 24.90% | |
| 23.24% | |
| 26.60% | |
| 27.50% | |
| 26.95% | |
| 24.92% | |
| 26.63% | |
| 26.52% | |
| 28.55% | |
| 25.71% | |
| 25.28% | |
| 26.49% | |
| 27.90% | |
| 27.40% | |
| 29.42% | |
| 27.94% | |
| 29.21% | |
| 34.88% | |
| 30.57% | |
| 31.05% | |
| 32.42% | |
| 31.31% | |
| 31.68% | |
| 45.60% | |
| 33.10% | |
| 34.65% | |
| 34.38% | |
| 34.88% | |
| 35.55% | |
| 34.09% | |
| 36.89% | |
| 38.27% | |
| 37.70% | |
| 41.31% | |
| 40.85% | |
| 43.87% | |
| 46.41% | |
| 47.57% | |
| 35.38% | |
| 32.17% |
Drug Manufacturers - General
GILD
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the…
More →GRFS
Description unavailable
More →GSK
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related…
More →JNJ
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a…
More →LLY
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125…
More →MRK
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in…
More →